{"prompt": "['the Schedule of Activities (Appendix 1', 'Schedule of Activities', ').', 'Drugs intended to control breakthrough bleeds (e.g. rFVII, FVIII, activated prothrombin complex concentrate', '[aPCC]) or bleeds during surgeries should be used at the lowest dose expected to achieve hemostasis. Given that', \"circulating emicizumab may increase the patient's coagulation potential, the doses required to achieve\", 'hemostasis may be lower than doses used prior to starting emicizumab. Investigators shall discuss at the start of', 'the study with patients recommended doses of any additional coagulation factors used, following the guidance', 'below.', 'The use of aPCC for breakthrough bleed treatment for patients on emicizumab should be avoided if possible, and', 'recombinant activated human Factor VII (rFVIIa) should be the first option used to treat, starting with no more', 'than 90 g/kg as an initial dose. If aPCC needs to be used, no more than 50 IU/kg should be administered as an', 'initial dose and doses of > 100 U/kg/24 hours or more should be avoided, as cases of TMA and thrombotic events', 'were reported when on average a cumulative amount of > 100 U/kg/24 hours aPCC was administered for 24', 'hours or more. Investigators should provide or remind patients of the exact dose and schedule of bypassing', 'agents or FVIII required to treat any bleed.', 'When a bleed has occurred, patients (or their legally authorized representative) will be required to', 'report bleed information on an ePRO device where possible, including site of bleed, type of bleed, time of', 'each individual bleed (day, start and stop time), and treatment for bleed (e.g., other than emicizumab', 'in case of breakthrough bleeds). The reason for the use of rFVIla will be documented (e.g., bleeding,', 'preventative dose before activity). Thorough documentation of the treatments for bleeds and/or', 'surgeries will be requested, including agent, start time, dose, route of administration, and number of', 'infusions needed to treat the bleed. Local and central laboratory assessments are required to monitor', 'the risk for thromboembolic events or microangiopathic hemolytic anemia or TMA, as per the Schedule of', 'Activities (Appendix 1', 'Schedule of Activities', '), if bypassing agents are used to treat a breakthrough bleed.', 'Investigators will be asked to contact the Medical Monitor in the event of suspected lack or loss of', 'efficacy of emicizumab in order to discuss a potential increase in emicizumab dose to 3 mg/kg/week', \"and additional laboratory evaluations (e.g., coagulation tests), as well as to re-evaluate the patient's\", 'individual benefit-risk for continuing treatment.', 'An independent Data Monitoring Committee (iDMC) will be responsible for monitoring safety throughout the', 'duration of the study.', 'Number of Patients', 'This global study will enroll approximately 200 patients with congenital hemophilia A who have', 'persistent inhibitors against FVIII at enrollment. The patients are expected to be enrolled at', 'approximately 85 sites globally.', 'Target Population', 'Inclusion Criteria', 'Patients must meet the following criteria for study entry:', '1. Signed Informed Consent Form', \"2. As per the investigator's judgement, a willingness and ability to comply with scheduled visits,\", 'treatment plans, laboratory tests, and other study procedures, including the patient-reported', 'outcome (PRO) questionnaires and bleed diaries through the use of an electronic device or paper', '3. Aged 12 years or older at the time of informed consent', '4. Diagnosis of congenital hemophilia A with persistent inhibitors against FVIII', '5. Documented treatment with bypassing agents or FVIII concentrates in the last 6 months (on-', 'demand or prophylaxis). Prophylaxis needs to be discontinued the latest by a day before starting', 'emicizumab', 'Emicizumab - F. Hoffmann-La Roche Ltd', '79 / Protocol MO39129, Version 3']['6. Adequate hematologic function, defined as platelet count 100,000/L and hemoglobin 8 g/dL', '(= 4.97 mmol/L) at the time of screening', '7. Adequate hepatic function, defined as total bilirubin < 1.5 x the upper limit of normal (ULN)', \"(excluding Gilbert's syndrome) and aspartate aminotransferase (AST) and alanine\", 'aminotransferase (ALT) 3 xULN at the time of screening; no clinical signs or known', 'laboratory/radiographic evidence consistent with cirrhosis', '8. Adequate renal function, defined as serum creatinine < 2.5 x ULN and creatinine clearance by', 'Cockcroft-Gault formula 30 mL/min', '9. For women of childbearing potential: agreement to remain abstinent (refrain from heterosexual', 'intercourse) or use a highly effective contraceptive method with a failure rate of < 1% per year', 'during the treatment period and for at least five elimination half-lives (24 weeks) after the last', 'dose of emicizumab:', 'A woman is considered to be of childbearing potential if she is postmenarcheal, has not', 'reached a postmenopausal state ( 12 continuous months of amenorrhea with no identified', 'cause other than menopause), and has not undergone surgical sterilization (removal of', 'ovaries and/or uterus)', 'Examples of highly effective contraceptive methods with a failure rate of < 1% per year', 'include proper use of combined oral or injected hormonal contraceptives, bilateral tubal', 'ligation, male sterilization, hormone-releasing intrauterine devices, and copper intrauterine', 'devices. Alternatively, two methods (e.g., two barrier methods such as a condom and a', 'cervical cap) may be combined to achieve a failure rate of < 1% per year. Barrier methods', 'must always be supplemented with the use of a non-lipid-based spermicide', 'The reliability of sexual abstinence should be evaluated in relation to the duration of the', 'clinical trial and the preferred and usual lifestyle of the patient. Periodic abstinence (e.g.,', 'calendar, ovulation, symptothermal, or postovulation methods) and withdrawal are not', 'acceptable methods of contraception.', 'Exclusion Criteria', 'Patients who meet any of the following criteria will be excluded from study entry:', '1. Inherited or acquired bleeding disorder other than hemophilia A', '2. Ongoing (or plan to receive during the study) immune tolerance induction (ITI) therapy', '(prophylaxis regimens with FVIII and/or bypassing agents must be discontinued prior to', 'enrollment). Patients receiving ITI therapy will be eligible following the completion of a 72-hour', 'washout period prior to the first emicizumab administration', '3.', \"History of illicit drug or alcohol abuse within 12 months prior to screening, as per the investigator's\", 'judgment', '4. High risk for TMA (e.g., have a previous medical or family history of TMA), as per the', \"investigator's judgment\", '5. Previous (in the past 12 months) or current treatment for thromboembolic disease (with the', 'exception of previous catheter-associated thrombosis for which antithrombotic treatment is not', 'currently ongoing) or current signs of thromboembolic disease', '6. Other conditions (e.g., certain autoimmune diseases) that may increase the risk of bleeding or', 'thrombosis', '7.', 'History of a clinically significant hypersensitivity reaction associated with monoclonal antibody', 'therapies or components of the emicizumab injection', '8.', 'Known human immunodeficiency virus (HIV) infection with CD4 count < 200 cells/L within', '6 months prior to screening', '9. Use of systemic immunomodulators (e.g., interferon or rituximab) at enrollment or planned use', 'during the study, with the exception of antiretroviral therapy', 'Emicizumab - F. Hoffmann-La Roche Ltd', '80 / Protocol MO39129, Version 3']\n\n###\n\n", "completion": "END"}